2021 GA Meeting May 12th, 14:00-15:30

2020 GA MEETING

 

The 2020 GA meeting which normally takes place in May was postponed to November 4th due to the global pandemic. The November 4th meeting which was virtual saw 20 attendees and lasted an hour as most of the GA mandated task/decisions were addressed by way of votes prior to the meeting. Chaired by Interim Chairman Dr Bernd Friede, the meeting though brief was effective with some key decisions taken as follows:

Some highlights:

  • Executive Committee: A new Executive team was endorsed with the 2nd Vice-Chairman becoming the Chairman and Secretary General maintained to ensure continuity
  • Non-EU letter of Access Fees: Letter of Access fees and administration fees for non-EU REACH-Like regulations per substance, per legal entity for non-MARA members was established
  • Members involvement in Non-EU regulations: MARA members wishing to register substances in non-EU REACH-like regulations will only pay administration fees as they own the data generated by MARA
  • Technical update: Three dossiers updated this year lead to a new classification for manganese based UVCB’s
  • 2020 Workplan and budget were ratified in Q1, 2020 via round robin votes.

Slags, SiMn-manufacturing (EC: 273-733-9; Cas 69012-33-5)

Dossier submission and History:

The lead dossier was submitted in 2010 with no testing proposals. In 2013 a compliance check was initiated, requesting more details with regard to the following information requirements/updates:

  • Annex IX, 8.6.2 (Sub-chronic study - 90days, Oral route, OECD 408)
  • Annex IX 8.7.2 (pre-natal developmental study, oral route, OECD 414)
  • Annex X, 8.7.3 (two-generation reproductive toxicity study, oral route, OECD 416 or an extended one generation reproductive toxicity study, OECD 443)

By Q4 2013 the consortium secretariat on behalf of the lead registrant had responded to the ECHA’s draft decision concerns, highlighting the lack of need for such animal-intensive studies for a substance that is not bioavailable.

After a second correspondence between ECHA and the lead registrant, the third correspondence was a compliance check final decision concluding that the following studies should be conducted:

  • Annex IX, 8.6.2 (Sub-chronic study - 90days, Oral route, OECD 408)
  • Pre-natal developmental toxicity study (Annex IX, 8.7.2.; test method: EU B.31/OECD 414) in rats or rabbits, oral route - readacross from FeMn slag

While a decision on the two-generation reproductive toxicity study endpoint was still pending, the dossier for this substance was updated with the above mentioned studies in Q3 2017 and successfully went through the compliance check.

In Q4 this year (2017), the Commission  requested that the lead registrant submits a dossier update with a testing proposal for an EOGRT study with a justiIfcation for the relevant cohort. 

An updated dossier was submitted - February 2018 with a justification on the lack of need for such an animal intensive study. This justification was accepted by the ECHA.

In Q1, 2019, all co-registrants that had met their financial obligations were provided with the following:

1) Updated CSR

2) Exposure scenarios for their eSDS

3) Updated CLP classification.

In Q3 2020 the dossierwas updated with a new classification. This update was triggered by a classifcation emanating from a Pre-natal developmental toxicity study (Annex IX, 8.7.2.; test method: EU B.31/OECD 414) in rats, oral route for FeMn slag - same readacross category. For more information contact reach@manganese.org or the ECHA  registration portal.

Note: Post 2018, the consortium will no longer invoice co-registrants  for ECHA requested studies retrospectively. All compliance check related work will require co-registrants to contribute their share before any dossier update work can begin. 

 

« Back to news


About cookies on our website

Following a revised EU directive on website cookies, each company based, or doing business, in the EU is required to notify users about the cookies used on their website.

Our site uses cookies to improve your experience of certain areas of the site and to allow the use of specific functionality like social media page sharing. You may delete and block all cookies from this site, but as a result parts of the site may not work as intended.

To find out more about what cookies are, which cookies we use on this website and how to delete and block cookies, please see our Which cookies we use page.

Click on the button below to accept the use of cookies on this website (this will prevent the dialogue box from appearing on future visits)